Insulin Resistance and T2D Associated With Gut Microbial Diversity
By LabMedica International staff writers Posted on 13 Aug 2021 |
The MiSeqDx System is the first FDA-regulated, CE-IVD-marked, NGS platform for in vitro diagnostic (IVD) testing (Photo courtesy of Illumina)
Type 2 diabetes (T2D) is a common complex metabolic disorder. Currently, more than 380 million people live with type 2 diabetes globally, and this number is expected to increase to more than 550 million by 2030.
Differences in gut microbiome composition with T2D status may comprise pathways on how dietary and other environmental factors affect development of insulin resistance and T2D. Patients with T2D have a lower overall α diversity of gut microbiome composition than healthy people.
A multidisciplinary international team of scientists led by those at the Erasmus University Medical Center (Rotterdam, the Netherlands) examined associations of gut microbiome composition with insulin resistance and T2D in a large population-based setting controlling for various sociodemographic and lifestyle factors. The team carried out a cross-sectional analysis included 2,166 participants from two Dutch population-based prospective cohorts.
The investigators used an automated stool DNA isolation kit (Diasorin, Saluggia, Italy) to isolate bacterial DNA. The V3 and V4 hypervariable regions of the bacterial 16S ribosomal RNA gene were amplified and sequenced on the MiSeq platform (Illumina, San Diego, CA, USA). Serum insulin was measured by electrochemiluminescence immunoassay technology. In one study, glucose levels were measured by hydrogen 1 nuclear magnetic resonance, and serum insulin was measured on an architect system (Abbott Laboratories, Lake Forest, IL, USA). Associations among α diversity, β diversity, and taxa with the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and with type 2 diabetes were examined.
The investigators reported that lower microbiome Shannon index and richness were associated with higher HOMA-IR (e.g., Shannon index, −0.06; 95% CI, −0.10 to −0.02), and patients with type 2 diabetes had a lower richness than participants without diabetes (odds ratio [OR], 0.93; 95% CI, 0.88-0.99). The β diversity)was associated with insulin resistance. A total of 12 groups of bacteria were associated with HOMA-IR or type 2 diabetes. There were five taxa whose higher abundance was tied to lower prevalence of T2D:Clostridiaceae 1, Peptostreptococcaceae, Clostridium sensu stricto 1, Intestinibacter, and Romboutsia. There were seven taxa whose greater abundance was associated with lower HOMA-IR including Christensenellaceae and Marvinbryantia.
The authors concluded that higher microbiome α diversity, along with more butyrate-producing gut bacteria, was associated with less T2D and with lower insulin resistance among individuals without diabetes. These findings could help provide insight into the etiology, pathogenesis, and treatment of T2D. The study was published on July 29, 2021 in the journal JAMA Network Open.
Related Links:
Erasmus University Medical Center
Diasorin
Illumina
Abbott Laboratories
Differences in gut microbiome composition with T2D status may comprise pathways on how dietary and other environmental factors affect development of insulin resistance and T2D. Patients with T2D have a lower overall α diversity of gut microbiome composition than healthy people.
A multidisciplinary international team of scientists led by those at the Erasmus University Medical Center (Rotterdam, the Netherlands) examined associations of gut microbiome composition with insulin resistance and T2D in a large population-based setting controlling for various sociodemographic and lifestyle factors. The team carried out a cross-sectional analysis included 2,166 participants from two Dutch population-based prospective cohorts.
The investigators used an automated stool DNA isolation kit (Diasorin, Saluggia, Italy) to isolate bacterial DNA. The V3 and V4 hypervariable regions of the bacterial 16S ribosomal RNA gene were amplified and sequenced on the MiSeq platform (Illumina, San Diego, CA, USA). Serum insulin was measured by electrochemiluminescence immunoassay technology. In one study, glucose levels were measured by hydrogen 1 nuclear magnetic resonance, and serum insulin was measured on an architect system (Abbott Laboratories, Lake Forest, IL, USA). Associations among α diversity, β diversity, and taxa with the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and with type 2 diabetes were examined.
The investigators reported that lower microbiome Shannon index and richness were associated with higher HOMA-IR (e.g., Shannon index, −0.06; 95% CI, −0.10 to −0.02), and patients with type 2 diabetes had a lower richness than participants without diabetes (odds ratio [OR], 0.93; 95% CI, 0.88-0.99). The β diversity)was associated with insulin resistance. A total of 12 groups of bacteria were associated with HOMA-IR or type 2 diabetes. There were five taxa whose higher abundance was tied to lower prevalence of T2D:Clostridiaceae 1, Peptostreptococcaceae, Clostridium sensu stricto 1, Intestinibacter, and Romboutsia. There were seven taxa whose greater abundance was associated with lower HOMA-IR including Christensenellaceae and Marvinbryantia.
The authors concluded that higher microbiome α diversity, along with more butyrate-producing gut bacteria, was associated with less T2D and with lower insulin resistance among individuals without diabetes. These findings could help provide insight into the etiology, pathogenesis, and treatment of T2D. The study was published on July 29, 2021 in the journal JAMA Network Open.
Related Links:
Erasmus University Medical Center
Diasorin
Illumina
Abbott Laboratories
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines